{"id":"NCT01474538","sponsor":"Eli Lilly and Company","briefTitle":"Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy","officialTitle":"A Randomized, Double-Blind, Crossover Trial Comparing the Safety and Efficacy of Insulin Lispro With the Safety and Efficacy of Insulin Aspart in Subjects With Type 2 Diabetes on CSII Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12","primaryCompletion":"2013-02","completion":"2013-02","firstPosted":"2011-11-18","resultsPosted":"2014-03-20","lastUpdate":"2014-03-20"},"enrollment":122,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Insulin Lispro","otherNames":["Humalog","LY275585"]},{"type":"DRUG","name":"Insulin Aspart","otherNames":["Novolog"]}],"arms":[{"label":"Insulin Lispro, then Insulin Aspart","type":"ACTIVE_COMPARATOR"},{"label":"Insulin Aspart, then Insulin Lispro","type":"ACTIVE_COMPARATOR"}],"summary":"This study will provide information on the use of insulin lispro and insulin aspart in insulin pumps in participants with type 2 diabetes.","primaryOutcome":{"measure":"Glycosylated Hemoglobin A1C (HbA1c) at Endpoint","timeFrame":"After 16 weeks of each treatment (Periods1 and 2)","effectByArm":[{"arm":"Insulin Lispro","deltaMin":7.5,"sd":0.12},{"arm":"Insulin Aspart","deltaMin":7.4,"sd":0.12}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":12,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":118},"commonTop":["Nasopharyngitis","Fatigue","Nausea","Sinusitis","Back pain"]}}